My watch list  

10,296 Current news from the ressort research


You can refine your search further. Select from the filter options on the left to narrow down your results.

ABB focuses research and development to drive growth


ABB, the global power and automation technology group, said today that it is streamlining its research and development to focus on technologies that increase productivity and sustainability for utility and industry customers, especially growth areas linked to its broad initiative called ...


Novartis creates new Singapore research institute for tropical diseases


Novartis announced today the establishment of a new tropical diseases research center in Singapore involving a SGD 220 million investment. The center will be called the Novartis Institute for Tropical Diseases and is the result of an agreement between Novartis and the Singapore Economic ...


ALTANA to establish Genomics Research Center in the US


In the course of its US strategy, Byk Gulden (Constance), the pharmaceuticals division of ALTANA AG, and GPC Biotech (Munich/Martinsried) will form a technology alliance in the fields of genomics/proteomics and bioinformatics. Together with its US subsidiary, ALTANA Inc., Byk Gulden will ...


Bristol-Myers Squibb And Otsuka Pharmaceutical Co., Ltd., Submit New Drug Application For Aripiprazole


Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Company, Ltd. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for aripiprazole, an investigational novel drug for the treatment of schizophrenia. If approved, ...


Agilent Technologies and Incyte Genomics Announce Patent Portfolio Agreement


Agilent Technologies Inc. (NYSE:A - news) and Incyte Genomics Inc. (Nasdaq:INCY - news), the leading genomic information company, today announced a comprehensive licensing agreement that gives Agilent access to Incyte's key microarray and gene expression patents and strengthens Agilent's position ...


Bristol-Myers Squibb Offers To Work With U.S. Government To Combat Bioterrorism


Bristol-Myers Squibb Company (NYSE:BMY) today announced actions in support of the campaign against bioterrorism. In a letter dated October 22 to Tommy G. Thompson, Secretary of the Department of Health and Human Services, Bristol-Myers Squibb Chairman and Chief Executive Officer Peter R. Dolan ...


Sigma-Genosys and Compugen Introduce Genome Libraries For High Throughput Analysis of Gene Function


Sigma-Genosys, a member of the Sigma-Aldrich family (NASDAQ:SIAL), and Compugen (NASDAQ:CGEN) announced today the commercial launch of OligoLibraries(TM), co-branded genome oligonucleotide collections for gene expression profiling, at the 13th International Genome Sequencing and Analysis ...


Merck KGaA Selects Forest Laboratories As U.S. Partner For Alcohol Addiction Treatment


Merck KGaA today announced that is has selected Forest Laboratories, Inc. (NYSE: FRX) as its U.S. partner for future marketing and distribution of acamprosate in the United States. A drug for the treatment of alcohol addiction, acamprosate has been approved in most major European markets as well ...


Amgen Dedicates Cambridge, Mass. Research Center Focusing On Small Molecule Drug Discovery


Amgen (NASDAQ:AMGN) today dedicated its 285,000 square foot research facility in the heart of the Cambridge-Boston biotechnology corridor. Amgen's work in the state-of-the-art, eight-story laboratory and research facility will focus on researching and discovering small molecule drug ...


Akzo Nobel and Shell to Jointly Develop Low Cost Solar Panels


Akzo Nobel and Shell Renewables have signed a joint development agreement to pilot a low cost process of mass-producing flexible solar cell panels. If the pilot project proves successful, it could help to overcome one of the main hurdles to widespread application of solar photovoltaics: its ...


Page 1021 From 1030
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE